Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 103337
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.103337
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.103337
Figure 4 Previously and currently available therapies and future prospects for immunotherapy in the management of pancreatic cancer in 2024.
Single agents and combinations of approved therapies or therapies under investigation in randomized clinical trials across tumor stages are shown. CAR-T: Chimeric antigen receptor-engineered T; TCR: T cell receptor.
- Citation: Hendi M, Zhang B, Mou YP, Cai XJ. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2025; 17(7): 103337
- URL: https://www.wjgnet.com/1948-5204/full/v17/i7/103337.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i7.103337